Glenna C. Bett, PhD, co-founded Cytocybernetics, a spin-off firm of UB that is developing biotechnology to enhance drug safety screening. The new technology could halve the time and money needed to bring new drugs to the market.
Our research spans from basic through translational and clinical, primarily focusing on determining the basic molecular bases of physiology and pathophysiology of women’s health and reproduction.
Topics include: